Cytori Therapeutics IncFind Ratings Reports
CYTORI THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. CYTORI THERAPEUTICS INC has weak liquidity. Currently, the Quick Ratio is 0.58 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 4.90% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||1.61||2.92|
|Net Income ($mil)||-7.54||-5.34|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||6.61||9.36|
|Total Assets ($mil)||29.77||32.92|
|Total Debt ($mil)||16.09||16.92|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||82.97||39.14|
|Return on Assets||-81.45||-6.45|
|Return on Equity||-329.36||-27.44|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||23.77||13.31|
|Div / share||0.0||0.0|
|Book value / share||0.31||0.58|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||715923.0||245623.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 3.07 indicates valuation on par with the S&P 500 average of 3.00 and a significant discount versus the industry average of 9.84. The price-to-sales ratio is above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CYTORI THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|CYTX NM||Peers 39.69||CYTX NM||Peers 41.03|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CYTX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CYTX's P/CF is negative making the measure meaningless.
|CYTX NA||Peers 23.10||CYTX NA||Peers 0.48|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CYTX 3.07||Peers 9.84||CYTX -740.00||Peers -13.13|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CYTX is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CYTX is expected to significantly trail its peers on the basis of its earnings growth rate.
|CYTX 2.24||Peers 108.22||CYTX -17.67||Peers 462.39|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CYTX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CYTX significantly trails its peers on the basis of sales growth